Riot Blockchain (RIOT) and Celldex Therapeutics (CLDX) Critical Review

Riot Blockchain (NASDAQ:RIOT) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Institutional & Insider Ownership

13.4% of Riot Blockchain shares are owned by institutional investors. Comparatively, 33.5% of Celldex Therapeutics shares are owned by institutional investors. 2.7% of Riot Blockchain shares are owned by insiders. Comparatively, 2.9% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Riot Blockchain has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Riot Blockchain and Celldex Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Riot Blockchain 0 0 1 0 3.00
Celldex Therapeutics 0 4 2 0 2.33

Riot Blockchain presently has a consensus price target of $4.00, indicating a potential upside of 61.29%. Celldex Therapeutics has a consensus price target of $4.50, indicating a potential upside of 997.56%. Given Celldex Therapeutics’ higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Riot Blockchain.

Profitability

This table compares Riot Blockchain and Celldex Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Riot Blockchain -1,383.44% -92.73% -67.70%
Celldex Therapeutics -1,159.26% -47.40% -33.86%

Earnings & Valuation

This table compares Riot Blockchain and Celldex Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Riot Blockchain $170,000.00 204.67 -$19.84 million ($2.71) -0.92
Celldex Therapeutics $12.74 million 5.23 -$93.03 million ($0.80) -0.51

Riot Blockchain has higher earnings, but lower revenue than Celldex Therapeutics. Riot Blockchain is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Celldex Therapeutics beats Riot Blockchain on 9 of the 13 factors compared between the two stocks.

About Riot Blockchain

Riot Blockchain, Inc. focuses on building, supporting, and operating blockchain technologies, primarily through its cryptocurrency mining operations and other developed businesses, as well as joint ventures, acquisitions, and targeted investments in the sector. Its primary focus is on Bitcoin and general blockchain technology. The company leverages its expertise and network to build and support blockchain technology companies. It builds a cryptocurrency mining operation and operates specialized computers that generate cryptocurrency, primarily Bitcoin. The company also holds interests in various activities, including purchasing and selling cryptocurrencies; providing accounting, audit, and verification services for blockchain based assets, such as cryptocurrencies; and developing TessPay, a payments ecosystem for component and sub-component supply chain settlements, and other blockchain solutions for telecommunications companies. As of March 31, 2018, approximately 3,500 of the miners were installed and operating. The company was formerly known as Bioptix, Inc. and changed its name to Riot Blockchain, Inc. in October 2017. Riot Blockchain, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.

Receive News & Ratings for Riot Blockchain Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Riot Blockchain and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply